{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:43:47Z","timestamp":1792637027281,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA196530"],"award-info":[{"award-number":["P50CA196530"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13058-018-1076-x","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T12:23:03Z","timestamp":1545049383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8431-1927","authenticated-orcid":false,"given":"Vasiliki","family":"Pelekanou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Villarroel-Espindola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt A.","family":"Schalper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"issue":"suppl","key":"1076_CR1","doi-asserted-by":"publisher","first-page":"abstr 506","DOI":"10.1200\/JCO.2017.35.15_suppl.506","volume":"35","author":"R Nanda","year":"2017","unstructured":"Nanda R, Liu MC, Yau C, Asare S, Hylton N, Van\u2019t Veer L, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. J Clin Oncol. 2017;35(suppl):abstr 506.","journal-title":"J Clin Oncol"},{"key":"1076_CR2","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34:2460\u20137.","journal-title":"J Clin Oncol"},{"key":"1076_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105\u201313.","journal-title":"J Clin Oncol"},{"key":"1076_CR4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983\u201391.","journal-title":"J Clin Oncol"},{"key":"1076_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/modpathol.2016.109","volume":"29","author":"C Denkert","year":"2016","unstructured":"Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016;29:1155\u201364.","journal-title":"Mod Pathol"},{"key":"1076_CR6","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","volume":"20","author":"KA Schalper","year":"2014","unstructured":"Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773\u201382.","journal-title":"Clin Cancer Res"},{"key":"1076_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","volume":"3","author":"H Wimberly","year":"2015","unstructured":"Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015;3:326\u201332.","journal-title":"Cancer Immunol Res"},{"key":"1076_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","volume":"47","author":"A Cimino-Mathews","year":"2016","unstructured":"Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47:52\u201363.","journal-title":"Hum Pathol"},{"key":"1076_CR9","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-14-1622","volume":"20","author":"JR Brown","year":"2014","unstructured":"Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Cancer Res. 2014;20:5995\u20136005.","journal-title":"Clin Cancer Res"},{"key":"1076_CR10","doi-asserted-by":"crossref","unstructured":"Coussens LM, Pollard JW. Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol. 2011;3:a003285.","DOI":"10.1101\/cshperspect.a003285"},{"key":"1076_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ni.3325","volume":"17","author":"I Amit","year":"2016","unstructured":"Amit I, Winter DR, Jung S. The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. Nat Immunol. 2016;17:18\u201325.","journal-title":"Nat Immunol"},{"key":"1076_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.trecan.2015.11.004","volume":"2","author":"RA Franklin","year":"2016","unstructured":"Franklin RA, Li MO. Ontogeny of Tumor-associated Macrophages and Its Implication in Cancer Regulation. Trends Cancer. 2016;2:20\u201334.","journal-title":"Trends Cancer"},{"key":"1076_CR13","doi-asserted-by":"crossref","unstructured":"Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer. 2016;2.","DOI":"10.1038\/npjbcancer.2015.25"},{"key":"1076_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1084\/jem.20150295","volume":"212","author":"A Mantovani","year":"2015","unstructured":"Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 2015;212:435\u201345.","journal-title":"J Exp Med"},{"key":"1076_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"1076_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coph.2014.07.004","volume":"17","author":"A Mantovani","year":"2014","unstructured":"Mantovani A, Vecchi A, Allavena P. Pharmacological modulation of monocytes and macrophages. Curr Opin Pharmacol. 2014;17:38\u201344.","journal-title":"Curr Opin Pharmacol"},{"key":"1076_CR17","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2014.00532","volume":"5","author":"M Rath","year":"2014","unstructured":"Rath M, Muller I, Kropf P, Closs EI, Munder M. Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages. Front Immunol. 2014;5:532.","journal-title":"Front Immunol"},{"key":"1076_CR18","doi-asserted-by":"crossref","unstructured":"Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, van Vugt MA, de Vries EG, et al. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. J Natl Cancer Inst. 2017;109.","DOI":"10.1093\/jnci\/djw192"},{"key":"1076_CR19","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.7150\/ijbs.15943","volume":"12","author":"L Gan","year":"2016","unstructured":"Gan L, Qiu Z, Huang J, Li Y, Huang H, Xiang T, et al. Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci. 2016;12:1533\u201343.","journal-title":"Int J Biol Sci"},{"key":"1076_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00428-012-1338-4","volume":"461","author":"AS Mansfield","year":"2012","unstructured":"Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M. The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. Virchows Arch. 2012;461:639\u201346.","journal-title":"Virchows Arch"},{"key":"1076_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1471-2407-12-306","volume":"12","author":"C Medrek","year":"2012","unstructured":"Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.","journal-title":"BMC Cancer"},{"key":"1076_CR22","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ijc.23527","volume":"123","author":"I Shabo","year":"2008","unstructured":"Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 2008;123:780\u20136.","journal-title":"Int J Cancer"},{"key":"1076_CR23","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7:e50946.","journal-title":"PLoS One"},{"issue":"suppl","key":"1076_CR24","doi-asserted-by":"publisher","first-page":"abstr TPS4141","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4141","volume":"35","author":"MA Shah","year":"2017","unstructured":"Shah MA, Metges J-P, Chun PY, Smith V, Maltzman JD, Wainberg ZA. A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2017;35(suppl):abstr TPS4141.","journal-title":"J Clin Oncol"},{"key":"1076_CR25","doi-asserted-by":"publisher","first-page":"e0127063","DOI":"10.1371\/journal.pone.0127063","volume":"10","author":"DC Marshall","year":"2015","unstructured":"Marshall DC, Lyman SK, McCauley S, Kovalenko M, Spangler R, Liu C, et al. Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS One. 2015;10:e0127063.","journal-title":"PLoS One"},{"key":"1076_CR26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm791","volume":"8","author":"RL Camp","year":"2002","unstructured":"Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323\u20137.","journal-title":"Nat Med"},{"key":"1076_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346\u201352.","journal-title":"Nature"},{"key":"1076_CR28","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.","journal-title":"Nat Commun"},{"key":"1076_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/annonc\/mdt556","volume":"25","author":"MV Dieci","year":"2014","unstructured":"Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611\u20138.","journal-title":"Ann Oncol"},{"key":"1076_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s13058-014-0488-5","volume":"16","author":"E Garcia-Martinez","year":"2014","unstructured":"Garcia-Martinez E, Gil GL, Benito AC, Gonzalez-Billalabeitia E, Conesa MA, Garcia Garcia T, et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16:488.","journal-title":"Breast Cancer Res"},{"key":"1076_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1158\/1078-0432.CCR-11-2762","volume":"18","author":"AM Gonzalez-Angulo","year":"2012","unstructured":"Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, et al. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012;18:1109\u201319.","journal-title":"Clin Cancer Res"},{"key":"1076_CR32","doi-asserted-by":"publisher","first-page":"e0135544","DOI":"10.1371\/journal.pone.0135544","volume":"10","author":"F Ren","year":"2015","unstructured":"Ren F, Tang R, Zhang X, Madushi WM, Luo D, Dang Y, et al. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0135544.","journal-title":"PLoS One"},{"key":"1076_CR33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/his.12607","volume":"66","author":"S Tiainen","year":"2015","unstructured":"Tiainen S, Tumelius R, Rilla K, Hamalainen K, Tammi M, Tammi R, et al. High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology. 2015;66:873\u201383.","journal-title":"Histopathology"},{"key":"1076_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.canlet.2013.01.024","volume":"332","author":"X Tang","year":"2013","unstructured":"Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332:3\u201310.","journal-title":"Cancer Lett"},{"key":"1076_CR35","doi-asserted-by":"publisher","first-page":"9188","DOI":"10.1038\/srep09188","volume":"5","author":"M Hollmen","year":"2015","unstructured":"Hollmen M, Roudnicky F, Karaman S, Detmar M. Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Sci Rep. 2015;5:9188.","journal-title":"Sci Rep"},{"key":"1076_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2014.11.004","volume":"358","author":"W Mou","year":"2015","unstructured":"Mou W, Xu Y, Ye Y, Chen S, Li X, Gong K, et al. Expression of Sox2 in breast cancer cells promotes the recruitment of M2 macrophages to tumor microenvironment. Cancer Lett. 2015;358:115\u201323.","journal-title":"Cancer Lett"},{"key":"1076_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gdata.2016.02.009","volume":"8","author":"F Roudnicky","year":"2016","unstructured":"Roudnicky F, Hollmen M. Transcriptional profiling of macrophage and tumor cell interactions in vitro. Genom Data. 2016;8:1\u20133.","journal-title":"Genom Data"},{"key":"1076_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13058-015-0621-0","volume":"17","author":"S Sousa","year":"2015","unstructured":"Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Monkkonen J, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17:101.","journal-title":"Breast Cancer Res"},{"key":"1076_CR39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/1471-2407-14-609","volume":"14","author":"EM Yousef","year":"2014","unstructured":"Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer. 2014;14:609.","journal-title":"BMC Cancer"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1076-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-018-1076-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1076-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T12:57:53Z","timestamp":1589547473000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-018-1076-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1186\/s13058-018-1076-x","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"30 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective research and tissue collection was reviewed and approved by Yale Human Investigation Committee protocol #9505008219 or #1010007459 (or both) prior to collection. The Yale Human Investigation Committee approved the patient consent forms (including publication of research data) or, in some cases, a waiver of consent. Images from tissue specimens are entirely unidentifiable and no details on individuals are reported within the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent for publication of research data was included in the consent forms and approved by the Yale Human Investigation Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DLR has served as an advisor for AstraZeneca, Agendia, Bristol-Myers Squibb, Cell Signaling Technology, Genoptix\/Novartis, Merck, and PerkinElmer. LP receives research funding from and served as consultant for Merck. KAS has served as an advisor for Celgene and Shattuck Labs and receives funding from Navigate Biopharma, Tesaro, Takeda, Onkaido Therapeutics, and Surface Oncology. VP is currently an employee of Sanofi. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"154"}}